Soluble ST2 as a marker of disease activity in systemic juvenile idiopathic arthritis

Cytokine

Volumn 62, Issue 2, 2013, Pages 272-277

  Ishikawa, Sayaka ^a   Shimizu, Masaki ^a   Ueno, Kazuyuki ^a   Sugimoto, Naotoshi ^a   Yachie, Akihiro ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

Interleukin 33; Juvenile idiopathic arthritis; ST2

Indexed keywords

BIOLOGICAL MARKER; INTERLEUKIN 33; PROTEIN ST2; RHEUMATOID FACTOR; UNCLASSIFIED DRUG; CELL SURFACE RECEPTOR; IL1RL1 PROTEIN, HUMAN; IL33 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE;

ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE MARKER; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HOST RESISTANCE; HUMAN; IMMUNOREGULATION; JUVENILE RHEUMATOID ARTHRITIS; LIMIT OF DETECTION; MALE; PATHOGENESIS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; SCHOOL CHILD; ADOLESCENT; BLOOD; INFANT; METABOLISM; YOUNG ADULT;

ADOLESCENT; ADULT; ARTHRITIS, JUVENILE; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INTERLEUKINS; MALE; RECEPTORS, CELL SURFACE; RHEUMATOID FACTOR; YOUNG ADULT;

EID: 84876792228     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2013.03.007     Document Type: Article

References (41)

1. Petty R.E., Southwood T.R., Manners P., Baum J., Glass D.N., Goldenberg J., et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton. J Rheumatol 2001, 31(2004):390-392.
2. Hinks A., Barton A., John S., Bruce I., Hawkins C., Griffiths C.E., et al. Association between the PTPN22gene and rheumatoid arthritis and juvenile idiopathic arthritis in a UK population: further support that PTPN22 is an autoimmunity gene. Arthritis Rheum 2005, 52:1694-1699.
3. Thomson W., Barrett J.H., Donn R., Pepper L., Kennedy L.J., Ollier W.E., et al. Rheumatology (Oxford) 2002, 41:1183-1189.
4. Kamphuis S., Hrafnkelsdottir K., Klein M.R., de Jager W., Haverkamp M.H., van Bilsen J.H., et al. Novel self-epitopes derived from aggrecan, fibrillin, and matrixmetalloproteinase-3 drive distinct autoreactive T-cell responses in juvenile idiopathic arthritis and in health. Arthritis Res Ther 2006, 8:R178.
5. Sikora K.A., Grom A.A. Update on the pathogenesis and treatment of systemic idiopathic arthritis. Curr Opin Pediatr 2011, 23:640-646.
6. Ravelli A., Grom A.A., Behrens E.M., Cron R.Q. Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment. Genes Immun 2012, 13:289-298.
7. Schmitz J., Owyang A., Oldham E., Song Y., Murphy E., McClanahan T.K., et al. aninterleukin-1-like cytokine that signals via the IL-1receptor-related protein ST2 and induces T helper type2-associated cytokines. Immunity 2005, 23:479-490.
8. Oboki K., Ohno T., Kajiwara N., Arae K., Morita H., Ishii A., et al. IL-33 is a crucial amplifier of innate rather than acquired immunity. Proc Natl Acad Sci USA 2010, 107:18581-18586.
9. Tominaga S., Jenkins N.A., Gilbert D.J., Copeland N.G., Tetsuka T. Molecular cloning of the murine ST2 gene: characterization andchromosomal mapping. Biochim Biophys Acta 1991, 1090:1-8.
10. Bergers G., Reikerstorfer A., Braselmann S., Graninger P., Busslinger M. Alternative promoter usage of the Fos-responsive gene Fit-1 generates mRNA isoforms coding for either secreted or membrane-bound proteins related to the IL-1 receptor. EMBO J 1994, 13:1176-1188.
11. Oshikawa K., Kuroiwa K., Tago K., Iwahana H., Yanagisawa K., Ohno S., et al. Elevated soluble ST2 protein levels in sera of patients with asthma with an acute exacerbation. Am J Respir Crit Care Med 2001, 164:277-281.
12. Komai-Koma M., Xu D., Li Y., McKenzie A.N., McInnes I.B., Liew F.Y. IL-33 is a chemoattractant for human Th2 cells. Eur J Immunol 2007, 37:2779-2786.
13. Moulin D., Donze O., Talabot-Ayer D., Mezin F., Palmer G., Gabay C. Interleukin (IL)-33 induces the release of pro-inflammatorymediators by mast cells. Cytokine 2007, 40:216-225.
14. Smithgall M.D., Comeau M.R., Yoon B.R., Kaufman D., Armitage R., Smith D.E. IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells. Int Immunol 2008, 20:19-1030.
15. Bourgeois E., Van L.P., Samson M., Diem S., Barra A., Roga S., et al. The pro-Th2 cytokine IL-33 directly interacts with invariant NKT and NK cells to induce IFN-gamma production. Eur J Immunol 2009, 39:1046-1055.
16. Kurowska-Stolarska M., Stolarski B., Kewin P., Murphy G., Corrigan C.J., Ying S., et al. IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation. J Immunol 2009, 183:6469-6477.
17. Rank M.A., Kobayashi T., Kozaki H., Bartemes K.R., Squillace D.L., Kita H. IL-33-activated dendritic cells induce an atypical TH2-type response. J Allergy Clin Immunol 2009, 123:1047-1054.
18. Yang Q., Li G., Zhu Y., Liu L., Chen E., Turnquist H., et al. IL-33 synergizes with TCR and IL-12 signaling to promote the effector function of CD8(?) T cells. Eur J Immunol 2011, 41:3351-3360.
19. Sweet M.J., Leung B.P., Kang D., Sogaard M., Schulz K., Trajkovic V., et al. A novel pathway regulating lipopolysaccharide-induced shock by ST2/T1 via inhibition of Toll-like receptor 4 expression. J Immunol 2001, 166:6633-6639.
20. Mok M.Y., Huang F.P., Ip W.K., Lo Y., Wong F.Y., Chan E.Y., et al. Serum levels of IL-33 and soluble ST2 and their association with disease activity in systemic lupus erythematosus. Rheumatology (Oxford) 2010, 49:520-527.
21. Tajima S., Oshikawa K., Tominaga S., Sugiyama Y. The increase in serum soluble ST2 protein upon acute exacerbation of idiopathic pulmonary fibrosis. Chest 2003, 124:1206-1214.
22. Weinberg E.O., Shimpo M., De Keulenaer G.W., MacGillivray C., Tominaga S., Solomon S.D., et al. Expression and regulation of ST2, an interleukin-1receptor family member, in cardiomyocytes andmyocardial infarction. Circulation 2002, 106:2961-2966.
23. Weinberg E.O., Shimpo M., Hurwitz S., Tominaga S., Rouleau J.L., Lee R.T. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation 2003, 107:721-726.
24. Ravelli A., Magni-Manzoni S., Pistorio A., Besana C., Foti T., Ruperto N., et al. Preliminarydiagnostic guidelines for macrophage activationsyndrome complicating systemic juvenile idiopathic arthritis. J Pediatr 2005, 146:598-604.
25. Wallace C.A., Ruperto N., Giannini E. Childhood Arthritis and Rheumatology Research Alliance; Pediatric Rheumatology International Trials Organization; Pediatric Rheumatology Collaborative Study Group. Preliminarycriteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 2004, 31:2290-2294.
26. Mellins E.D., Macaubas C., Grom A.A. Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions. Nat Rev Rheumatol 2011, 7:416-426.
27. Leung B.P., Xu S., Culshaw S., McInnes I.B., Liew F.Y. A novel therapy of murine collagen-induced arthritis with soluble T1/ST2. J Immunol 2004, 173:145-150.
28. Jiang H.R., Milovanović M., Allan D., Niedbala W., Besnard A.G., Fukada S.Y., et al. IL-33 attenuates experimental autoimmune encephalomyelitis by suppressing IL-17 and IFN-γ production and inducing alternatively-activated macrophages. Eur J Immunol 2012, 42:1804-1814.
29. Matsuyama Y., Okazaki H., Tamemoto H., Kimura H., Kamata Y., Nagatani K., et al. Increased levels of interleukin 33 in sera and synovial fluid from patients with active rheumatoid arthritis. J Rheumatol 2010, 37:18-25.
30. Mu R., Huang H.Q., Li Y.H., Li C., Ye H., Li Z.G. Elevated serum interleukin 33 is associated with autoantibody production in patients with rheumatoid arthritis. J Rheumatol 2010, 37:2006-2013.
31. Xiangyang Z., Lutian Y., Lin Z., Liping X., Hui S., Jing L. Increased levels of interleukin-33 associated with bone erosion and interstitial lung diseases in patients with rheumatoid arthritis. Cytokine 2012, 58:6-9.
32. Han G.W., Zeng L.W., Liang C.X., Cheng B.L., Yu B.S., Li H.M., et al. Serum levels of IL-33 is increased in patients with ankylosing spondylitis. Clin Rheumatol 2011, 30:1583-1588.
33. Hong Y.S., Moon S.J., Joo Y.B., Jeon C.H., Cho M.L., Ju J.H., et al. Measurement of interleukin-33 (IL-33) and IL-33 receptors (sST2 and ST2L) in patients with rheumatoid arthritis. J Korean Med Sci 2011, 26:1132-1139.
34. Talabot-Ayer D., McKee T., Gindre P., Bas S., Baeten D.L., Gabay C., et al. Distinct serum and synovial fluid interleukin (IL)-33 levels in rheumatoid arthritis, psoriatic arthritis and osteoarthritis. Joint Bone Spine 2012, 79:32-37.
35. Matsuyama Y., Okazaki H., Hoshino M., Onishi S., Kamata Y., Nagatani K., et al. Sustained elevation of interleukin-33 in sera and synovial fluids from patients with rheumatoid arthritis non- responsive to anti-tumor necrosis factor: possible association with persistent IL-1β signaling and a poor clinical response. Rheumatol Int 2012, 32:1397-1401.
36. Mu R., Huang H.Q., Li Y.H., Li C., Ye H., Li Z.G. Elevated serum interleukin 33 is associated with autoantibody production in patients with rheumatoid arthritis. J Rheumatol 2010, 37:2006-2013.
37. Matsuyama Y., Okazaki H., Tamemoto H., Kimura H., Kamata Y., Nagatani K., et al. Increased levels of interleukin 33 in sera and synovial fluid from patients with active rheumatoid arthritis. J Rheumatol 2010, 37:18-25.
38. Carriere V., Roussel L., Ortega N., Lacorre D.A., Americh L., Aguilar L., et al. IL-33, the IL-1-likecytokine ligand for ST2 receptor, is a chromatin-associatednuclear factor in vivo. Proc Natl Acad Sci USA 2007, 104:282-287.
39. Trajkovic V., Sweet M.J., Xu D. T1/ST2 an IL-1receptor-like modulator of immune responses. Cytokine Growth Fact Rev 2004, 15:87-95.
40. Mildner M., Storka A., Lichtenauer M., Mlitz V., Ghannadan M., Hoetzenecker K., et al. Primary sources and immunological prerequisites for sST2 secretion in humans. Cardiovasc Res 2010, 87:769-777.
41. Bartunek J., Delrue L., Van Durme F., Muller O., Casselman F., De Wiest B., et al. Nonmyocardial production of ST2 protein in human hypertrophy and failure is related to diastolic load. J Am Coll Cardiol 2008 Dec 16, 52(25):2166-2174.